Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Follow-up for patients with malignancies after radical treatment: unresolved questions

Follow-up for patients with malignancies after radical treatment: unresolved questions editorial memo (2014) 7:78–79 DOI 10.1007/s12254-014-0150-z Follow-up for patients with malignancies after radical treatment: unresolved questions Vladimir Moiseyenko Received: 27 May 2014 / Accepted: 27 May 2014 / Published online: 3 July 2014 © Springer-Verlag Wien 2014 Contemporary clinical practice is supported by a vari- Now, it is obvious that treatment, as well as the FU ety of international evidence-based standards (NCCN, approach, should be individualized urgently. The sched- ASCO, ESMO, NCI, NICE, etc.) that determine optimal ule and structure of the FU procedures should differ by approach for patients with malignancies after the carried biologic considerations (tumor morphology, disease out treatment. Essentially, they can be divided into stage, tumor grade, sensitivity to conventional treatment, following groups: median time of relapse after treatment, recurrence fre- quency, and sites), medical considerations—opportu- 1. Identification of disease recurrence in patients with nities of radical treatment in case of disease recurrence radical treatment for the subsequent effective therapy (effective cytotoxic drugs or the target therapy, relatively (anal cancer, colorectal cancer, sarcomas, lymphopro- radical second-look surgical procedures, and radical liferative disorders, germ cell tumors), schedules of radiation), and unfortunately also social 2. monitoring of the necessity of interventions in and economic considerations (geographical region, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Follow-up for patients with malignancies after radical treatment: unresolved questions

Loading next page...
 
/lp/springer-journals/follow-up-for-patients-with-malignancies-after-radical-treatment-xGZw0TEYDZ

References (2)

Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0150-z
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2014) 7:78–79 DOI 10.1007/s12254-014-0150-z Follow-up for patients with malignancies after radical treatment: unresolved questions Vladimir Moiseyenko Received: 27 May 2014 / Accepted: 27 May 2014 / Published online: 3 July 2014 © Springer-Verlag Wien 2014 Contemporary clinical practice is supported by a vari- Now, it is obvious that treatment, as well as the FU ety of international evidence-based standards (NCCN, approach, should be individualized urgently. The sched- ASCO, ESMO, NCI, NICE, etc.) that determine optimal ule and structure of the FU procedures should differ by approach for patients with malignancies after the carried biologic considerations (tumor morphology, disease out treatment. Essentially, they can be divided into stage, tumor grade, sensitivity to conventional treatment, following groups: median time of relapse after treatment, recurrence fre- quency, and sites), medical considerations—opportu- 1. Identification of disease recurrence in patients with nities of radical treatment in case of disease recurrence radical treatment for the subsequent effective therapy (effective cytotoxic drugs or the target therapy, relatively (anal cancer, colorectal cancer, sarcomas, lymphopro- radical second-look surgical procedures, and radical liferative disorders, germ cell tumors), schedules of radiation), and unfortunately also social 2. monitoring of the necessity of interventions in and economic considerations (geographical region,

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jul 3, 2014

There are no references for this article.